Clinical Scorecard: MHRA Approval for First UK-made mRNA Vaccine

At a Glance

Key Highlights

• First UK-made mRNA vaccine authorized by MHRA
• Targets the SARS-CoV-2 LP.8.1 variant
• Supplied from the Moderna Innovation and Technology Centre in Oxfordshire
• Supports the 2026 NHS COVID-19 vaccination campaign
• Strengthens UK's pandemic preparedness and vaccine manufacturing capability

Guideline-Based Recommendations

Diagnosis

• Monitor COVID-19 variants and update vaccine composition accordingly

Management

• Administer updated Spikevax® vaccine to eligible populations

Monitoring & Follow-up

• Evaluate vaccine efficacy against circulating variants

Risks

• Consider potential adverse effects and public health implications of COVID-19

Patient & Prescribing Data

Adults and children aged six months and above

Updated vaccine is essential for protecting high-risk groups

Clinical Best Practices

• Ensure timely access to updated vaccines
• Promote vaccination campaigns targeting vulnerable populations
• Collaborate with public health agencies for effective distribution

References

• MHRA Approval Announcement
• WHO TAG-CO-VAC Recommendations